EARLY EXPERIENCE OF GPP-1 LIRAGLUTIDE 3.0 MG ANALOGUE IN RUSSIA AND ITS EFFECT ON METABOLIC RISK FACTORS IN OBESITY PATIENTS
Obesity is a chronic disease associated with cardiometabolic risk factors of cardiovascular diseases and type 2 diabetes. In 2016, in Russia a new drug was registered for the treatment of patients with adiposity - liraglutide 3.0 mg, which is an analog of human glucagonoma peptide-1. The study purpo...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Russo |
| Veröffentlicht: |
Remedium Group LLC
2017-12-01
|
| Schriftenreihe: | Медицинский совет |
| Schlagworte: | |
| Online-Zugang: | https://www.med-sovet.pro/jour/article/view/1751 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|